True North Advisors 13F: Adds $1.3M to Eli Lilly and (LLY) Stake

True North Advisors expanded its holdings in Eli Lilly and Company LLY during the third quarter, purchasing an additional 1,108 shares to bring its total stake to 4,217 shares. The investment was disclosed in a Form 13F filing with the SEC on October 22, 2026.

LLY Eli Lilly and Company

$1,306.74 ▲ +21.54% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in True North Advisors's Eli Lilly and Company Position

True North Advisors increased its investment in Eli Lilly and Company LLY by 35.6%, lifting its share count from 3,103 to 4,217 shares. The reported value of the stake reached $4,879,120 at the time of the filing.

Other Institutional Activity in Eli Lilly and Company

Other major institutional investors adjusted their positions in Eli Lilly and Company LLY around the same period. Wealthcare Advisory Partners grew its holdings by 2,980 shares, ending with 13,284 shares worth about $15.4 million following a 28.9% increase. Symphony Financial grew its holdings by 1,205 shares, ending with 7,802 shares worth about $9.2 million following an 18.3% increase. Strategic Blueprint lowered its holdings by 785 shares, ending with 12,911 shares worth about $14.9 million after a 5.7% decrease. Lilly Endowment, Inc reduced its holdings by 307,272 shares, ending with 90,066,978 shares worth about $117.7 billion following a 0.3% decrease. PNC Financial Services Group, Inc. reduced its holdings by 5,133 shares, ending with 51,322,720 shares worth about $67.1 million.

Eli Lilly and Company Stock Up 1.8%

Eli Lilly and Company LLY recently traded around $1,306.74 as of October 23, 2026, which is about equal to its close of $1,306.69 on the filing date. The stock trades well above both its 50-day moving average of $1,183.59 and its 200-day moving average of $1,082.90. Shares sit just below the 52-week high of $1,311.75 and far above the 52-week low of $806.02.

Recent Earnings

Eli Lilly and Company LLY posted trailing-twelve-month revenue of $79.67 billion and earnings of $29.79 per share. The company reported a net profit margin of 33.5% and a return on equity of 102.3%. Its year-over-year revenue growth reached 47.7%. The drug manufacturer is scheduled to release its next round of financial results on October 29, 2026.

Dividend

Eli Lilly and Company LLY pays an annual dividend rate of $6.92 per share, giving investors a dividend yield of 0.54%. The company maintains a dividend payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several transactions prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total value of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share totaling $7,638,150.

Analysts Set New Price Targets

Wall Street research firms updated their outlooks on Eli Lilly and Company LLY ahead of the filing. JP Morgan maintained an Overweight rating on September 28, 2026, while raising its target to $1,500.00 from $1,400.00. Morgan Stanley maintained an Overweight rating on October 7, 2026, lifting its target to $1,430.00 from $1,419.00. Cantor Fitzgerald maintained an Overweight rating on October 8, 2026, moving its target from $1,410.00 to $1,440.00. RBC Capital reiterated an Outperform rating on October 12, 2026, with a target of $1,500.00. Leerink Partners maintained an Outperform rating on October 21, 2026, raising its target to $1,316.00 from $1,309.00. Across the broader analyst community, the stock holds a buy consensus with a mean price target of $1,331.55.

About Eli Lilly and Company

Headquartered in Indianapolis, Indiana, Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The healthcare giant focuses on treatments across multiple major therapeutic categories. Its established portfolio and research pipeline make it a key holding for institutional portfolios tracking the drug manufacturing sector.

Bottom Line

True North Advisors expanded its exposure to Eli Lilly and Company LLY during a period of strong momentum for the stock. Investors will look toward the upcoming earnings release on October 29, 2026, for further updates on the company's financial trajectory.